Gilead/Kite’s Tecartus Moves Into Leukemia With Second US Indication

 
• By Joseph Haas

New indication for second-line-plus acute lymphoblastic leukemia means Tecartus will compete with Novartis’s Kymriah, although the Gilead/Kite product is approved for older patient base.

3d illustration of immune system T cells attacking cancer cells (CAR T-cell therapy) - Illustration
Kite obtains its second FDA approval for cell therapy Tecartus

More from New Products

More from Scrip